Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report issued on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also commented on ATNM. B. Riley set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, December 27th. Zacks Investment Research upgraded Actinium Pharmaceuticals from a hold rating to a buy rating and set a $0.75 price objective for the company in a research report on Monday, December 25th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $3.75.

How to Become a New Pot Stock Millionaire

Actinium Pharmaceuticals (ATNM) opened at $0.36 on Tuesday. Actinium Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $1.68. The stock has a market capitalization of $32.44, a PE ratio of -0.77 and a beta of 40.64.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. raised its stake in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 157,000 shares of the biotechnology company’s stock after buying an additional 109,000 shares during the quarter. D.A. Davidson & CO. owned about 0.20% of Actinium Pharmaceuticals worth $104,000 at the end of the most recent reporting period.

TRADEMARK VIOLATION WARNING: “Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by Maxim Group Analysts” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.